Financial Lp Hrt Sells 9,022 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $3.51, for a total transaction of $31,667.22. Following the sale, the insider owned 81,385 shares in the company, valued at approximately $285,661.35. This trade represents a 9.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.30 per share, for a total transaction of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Price Performance

Shares of SHPH traded down $0.24 on Tuesday, hitting $3.26. The company’s stock had a trading volume of 109,982 shares, compared to its average volume of 543,961. The company has a market capitalization of $2.08 million, a PE ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a fifty-two week low of $2.90 and a fifty-two week high of $55.90. The company has a 50 day moving average price of $5.57 and a 200 day moving average price of $10.46.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals during the 4th quarter worth $26,000. Boothbay Fund Management LLC bought a new position in Shuttle Pharmaceuticals during the fourth quarter worth about $37,000. Ikarian Capital LLC acquired a new position in Shuttle Pharmaceuticals during the fourth quarter valued at approximately $124,000. Finally, Connective Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals during the 3rd quarter worth $357,000. 4.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .